Conor Hale

Medtronic has secured FDA approval for its first closed-loop spinal cord stimulator, designed to take in signals from the body and adjust its therapy automatically.

Abbott has returned to the field of bio-absorbable, dissolving stents, and in somewhat uncharted territory.

The FDA has finalized its regulatory rule that aims to bring laboratory-developed tests more in-line with how the agency oversees other diagnostics.

The FDA has bestowed a green light to a companion diagnostic for Pfizer's recently approved hemophilia B gene therapy—because at a cost of $3.5 million per dose, you want to make sure it will work.

Philips has reached an $1.1 billion agreement to settle claims from about 58,000 people stemming from its years-long recall of home CPAP ventilators and sleep apnea machines.

GE HealthCare missed its revenue goals for the first quarter after sales in China dipped 11%, compared to the boosts the company saw in the region during the same period the year prior.

Quest Diagnostics is building out its artificial intelligence-powered cancer pathology offerings through a multi-layered deal with PathAI—acquiring some assets, licensing out others.

Hologic is putting down about $310 million to acquire Endomagnetics, the developer of technologies for localizing tumors in breast cancer surgeries without using radioactive materials.

The hospital supply giant Medline is bolstering its presence in the operating room, with a plan to acquire Ecolab's surgical solutions division at a price just shy of $1 billion.

The U.S.